Clinical-stage immunotherapy firm ImmunityBio (NASDAQ: IBRX), completes accrual of the first two phases of a national trial assessing its Nant Cancer Vaccine (NCV) in participants with Lynch syndrome.
Utilising a tri-valent Adenovirus (Tri-Ad5) combined with IL-15 superagonist N-803, the trial aims to prevent colon and other cancers.
Lynch syndrome, associated with a genetic mutation, elevates cancer risks.
ImmunityBio's study progresses to the randomised controlled phase, aiming to enroll up to 186 individuals.
The vaccine targets cancer-specific proteins to activate natural killer and T cells for potential cancer prevention. ImmunityBio's investigational Tri-Ad5 Vaccines and N-803 continue to be studied for safety and efficacy, with a focus on preventing colorectal and other cancers associated with Lynch syndrome.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration